PhRMA names new SVP federal advocacy
WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced the appointment of Charles “Chuck” Clapton to the position of SVP federal advocacy, effective March 17, 2014.
In this capacity, Clapton will be responsible for leading PhRMA’s federal government affairs initiatives and advancing its legislative agenda, working with stakeholders to develop and advocate for health policies that foster innovation and ensure patient access to new medicines in the United States and around the world.
He will report to Chip Davis, EVP advocacy and member relations.
“Chuck is a dynamic advocate and an expert on the policy issues facing the biopharmaceutical sector and the patients we serve,” said John Castellani, president and CEO of PhRMA. “He will make important contributions to our work with policymakers on promoting research and innovation and making progress for patients.”
Most recently, Clapton worked as a partner at the international law firm HoganLovells, where he represented healthcare clients on legislative and regulatory matters. Prior to joining HoganLovells, Clapton worked for 17 years on Capitol Hill, where he held several leadership positions on the House Energy & Commerce Committee, Ways & Means Committee, Office of the Speaker and the Senate Health, Education, Labor and Pensions Committee.
“Chuck’s experience, reputation and results-oriented focus during his distinguished career on Capitol Hill will be tremendous assets to PhRMA and its members as he leads our federal advocacy efforts,” Davis said.
During his time with the House and Senate, Clapton worked on reimbursement and coverage initiatives, including the Medicare Modernization Act that created the highly successful Medicare Part D drug program. In addition, he has extensive experience with policy issues related to Food and Drug Administration review and approval of new medicines, the distribution and use of non-FDA approved drugs, and other critical patient safety matters.
Clapton earned his J.D. from the Catholic University, Columbus School of Law and B.A. from Boston College.
Dr. Reddy’s launches Sumatriptan
HYDERABAD, India — Dr. Reddy’s Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL. The drug is available in a carton containing 2 single-dose prefilled syringes.
Sumatriptan is used to treat acute migraine headaches with or without aura and acute cluster headaches in adults who have been diagnosed with migraine or cluster headaches, according to the company.
The Imitrex STATdose Pen brand, along with the generic had combined U.S. sales of approximately $169 million for the twelve months ending in December 2013, according to IMS Health.
NACDS supports bill to curb Rx abuse, safeguard patients
ARLINGTON, Va. — U.S. House of Representatives Energy and Commerce Committee vice chair Marsha Blackburn, R-Tenn., and Rep. Tom Marino, R-Pa., have introduced legislation that would establish a work group to explore opportunities to reduce prescription drug abuse without compromising access to medications for patients who legitimately need them.
The National Association of Chain Drug Stores on Tuesday expressed its support for the new legislation — the Ensuring Patient Access and Effective Drug Enforcement Act of 2013 (H.R. 4069).
“NACDS and chain pharmacy are committed to partnering with federal and state agencies, law enforcement personnel, policy-makers, and other stakeholders to work on viable strategies to simultaneously advance patient health and prevent prescription drug abuse,” stated NACDS president and CEO Steve Anderson. “This legislation is an important step in addressing one of the most complex public health problems of our day.”
The workgroup would include equitable representation of healthcare and law enforcement entities up to 20 individuals. It would include representatives of the FDA, the Drug Enforcement Administration and the White House Office of National Drug Control Policy, as well as organizations representing patients, pharmacy, prescribers, hospitals, wholesalers, state attorneys general, law enforcement officials, and others with expertise in this area.
“It makes perfect sense that problems like drug abuse and meeting patients’ needs merit the highest form of collaboration among experts in government and in the private sector, but the best of intentions do not always provide that. We commend Reps. Marino and Blackburn for moving forward with this important concept,” Anderson added.
In its continued efforts to curb prescription drug abuse and diversion and ensure patient access to medications, NACDS has previously supported legislation introduced by U.S. Sen. Barbara Boxer to collaboratively address the problem through collaboration with law enforcement and healthcare stakeholders.